Cadila Healthcare is currently trading at Rs. 366.95, up by 3.70 points or 1.02% from its previous closing of Rs. 363.25 on the BSE.
The scrip opened at Rs. 379.80 and has touched a high and low of Rs. 380.00 and Rs. 364.00 respectively. So far 166075 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 383.65 on 15-Jun-2020 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 380.00 and Rs. 347.05 respectively. The current market cap of the company is Rs. 37648.13 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.45% and 7.67% respectively.
Zydus Cadila’s plasmid DNA vaccine candidate for COVID-19 has successfully completed the preclinical phase and has now received permission from the Drug Controller General of India – Central Drugs Standard Control Organisation (CDSCO) to initiate Phase I/II human clinical trials in India. In animal studies the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to completely neutralize the wild type virus in virus neutralization assay indicating the protective potential of the vaccine candidate.
The company has already manufactured clinical GMP batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1000 subjects.
Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
